The hemopoietic regulator multipotential colony-stimulating factor [Multi-CSF (interleukin 3)] has proliferative effects on a wide range of hemopoietic cells in vitro and in vivo. Native or recombinant Multi-CSF injected intravenously into adult mice had an initial half-life of 3-5 min and a second phase of 50 min. Clear labeling of hemopoietic cells was observed in the bone marrow and spleen of mice injected intravenously with recombinant '25I-labeled Multi-CSF show-ing that injected Multi-CSF can obtain access to such cells in situ. A high proportion of injected 12I-labeled Multi-CSF of
both types became localized in the liver and in the kidney (in cells of the Bowman's capsule and proximal renal tubules). The kidney appeared to be an active site of degradation of Multi-CSF with the early appearance of low molecular weight labeled material in the urine.
The glycoprotein colony-stimulating factors (CSFs) are regulators that interact to control the proliferation and functional activity of granulocytes, macrophages, and related hemopoietic populations (1) . One of these, multipotential CSF [Multi-CSF (interleukin 3)], is distinguished by its exceptionally broad range of responding hemopoietic populations. Multi-CSF stimulates the proliferation not only of granulocyte and macrophage precursor cells but also of precursors of erythroid cells, eosinophils, megakaryocytes, mast cells, and multipotential cells, some of the latter being hemopoietic stem cells (2) (3) (4) .
Following the cloning of cDNAs for Multi-CSF (5, 6) , it was shown that biologically active recombinant Multi-CSF (rMulti-CSF) could be produced by using mammalian and bacterial expression systems (7) (8) (9) (10) . Injection of rMulti-CSF into mice produced increases in hemopoietic populations in agreement with expectations from the known direct effects of Multi-CSF in vitro (10) (11) (12) (13) (14) .
To substantiate that the observed effects in vivo of injected Multi-CSF are likely to be due to the direct actions of the molecule, 125I-labeled Multi-CSF (125I-Multi-CSF) was used to determine whether injected Multi-CSF can reach and bind to relevant hemopoietic cells in the marrow and spleen. The studies also determined the serum half-life, organ distribution, and fate of injected Multi-CSF.
MATERIALS AND METHODS
Multi-CSF and lodinations. Nonglycosylated rMulti-CSF was a gift from J. DeLamarter (Biogen, Geneva) and was purified to homogeneity as described (11) . Native glycosylated Multi-CSF from the concanavalin A-activated T-cell clone LB-3 was purified to homogeneity by sequential chromatography on red A-agarose, Sephadex G-75, and reversephase HPLC. One to 4 f.g of both forms of Multi-CSF was iodinated and repurified as described (15) . lodinated Multi-CSFs retained >90% of biological activity and had specific radioactivities ranging from 5 x 104 to 3 x 1i0 cpm/ng. Injection of Mice. '25I-Multi-CSF in Dulbecco's modified Eagle's medium containing 10% fetal calf serum was injected into C57BL/6 WEHI female mice aged 60-76 days. In different experiments 4 x 10W-3 x 106 cpm of 1251-Multi-CSF in 0.2 ml was injected into a tail vein, into the peritoneal cavity, or s.c. Blood was collected from the orbital plexus into 50-,lI Micropets (Clay Adams) or by exsanguination.
Processing of Blood and Organs. The blood was expelled from the Micropets into 1 ml of distilled water and allowed to lyse, and radioactivity was counted by using a Packard Autogamma counter operating at 75% efficiency (5-min counts). Samples were then put on ice, 2 ml of 30% trichloroacetic acid was added, and the mixture was allowed to stand for 10 min. Samples were centrifuged at 10,000 x g for 20 min, the supernatant was removed, and the precipitate was washed with 30% trichloroacetic acid and then counted for radioactivity. Organs (kidney, liver, spleen, gut, salivary gland, thymus, muscle, ovary, lung, heart, thyroid) were removed, weighed, and assayed for radioactivity. In some cases, organs were fixed in 2.5% glutaraldehyde in phosphate-buffered (0.02 M, pH 7.4) saline (0.15 M) and sections were prepared for autoradiography. Bone marrow cells and blood buffy coat cells were washed three times by centrifugation (700 x g, 5 min) through fetal calf serum, smears were prepared by cytocentrifuge, and the slides were fixed as above.
Autoradiography. Tissue sections or cell smears on gelatin-coated glass slides were coated with photographic emulsion at 420C, exposed for 2 weeks to 1 month, and developed as described (15) . After development and fixation, cytocentrifuge preparations were stained with 5% Giemsa solution in phosphate-buffered saline and sections were stained with hematoxylin/eosin. Bioassays for Multi-CSF. Bioassays of purified native Multi-CSF and rMulti-CSF preparations for colony-stimulating activity were performed in standard agar cultures of 75,000 C57BL marrow cells (1) . Units of activity were determined by assigning 50 units/ml to the concentration stimulating the formation of half-maximal numbers of granulocyte/macrophage colonies. Both preparations had a specific activity of 5-7 x 108 units/mg of protein. Serum levels of Multi-CSF were assayed by using microwell cultures of 200 32D clone 3 cells responsive to stimulation only by Multi-CSF (16) . Levels of Multi-CSF were converted to units/ml by the inclusion in each assay of a Multi-CSF preparation of known colony-stimulating activity. Absence of inhibitory activity in various serum samples was verified in mixing experiments by using a known concentration of Multi-CSF.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. injection of 125I-labeled rMulti-CSF (1251-rMulti-CSF), there was an initial rapid fall in trichloroacetic acid-precipitable cpm, with a half-life of 3-5 min; this was followed by a slower second phase with an apparent half-life of 5 hr ( Fig.  1 ). However, bioassays on the sera of mice injected with rMulti-CSF revealed that the initial half-life phase extended for 30 min, by which time levels had fallen to 0.5% of initial levels, and that this was followed by a second phase in which the half-life was only 50 min (Fig. 2) . The marked discrepancy between the two assays was not due to the presence of inhibitors in the sera and indicated that much of the trichloroacetic acid-precipitable labeled material, although macromolecular, was biologically inactive, possibly due to partial degradation.
Parallel studies using native 1251-Multi-CSF indicated similar kinetics in the first 2 hr to those for rMulti-CSF (data not shown) so that the short serum half-life of bacterially synthesized Multi-CSF was not ascribable to the lack of glycosylation or abnormal refolding of the recombinant mole- Similar discrepancies between the half-life of injected rMulti-CSF as determined by cpm on radiolabeled material versus bioassays were observed when rMulti-CSF was injected either s.c. or i.p. (Figs. 1 and 2 ). Only by bioassay was it demonstrable that injection by these latter routes achieved more sustained elevations of serum Multi-CSF levels than did injection by the i.v. route.
Blood and Organ Distribution of i.v.-Injected Multi-CSF. By 5 hr after i.v. injection, more native 121I-Multi-CSF had been cleared from the blood and most organs than 125[_ rMulti-CSF (Table 1 ). The organ distribution pattern was dominated by extremely high levels localized to the liver and kidney, but in these organs levels of native 121I-Multi-CSF were higher than those of 125I-rMulti-CSF. Assuming that the only difference between these two molecules is the attachment of carbohydrate on native Multi-CSF, this suggests that carbohydrate may slow degradation of Multi-CSF in the liver and kidneys.
The sequential pattern of organ localization was determined in more detail by an analysis of mice killed at earlier intervals after the i.v. injection of 125I-rMulti-CSF. cpm rose extremely rapidly in the liver to reach peak levels 2-10 min after injection; these levels then fell progressively ( Fig. 3) . A comparable, but slightly delayed, rise in radiolabeling was observed in the kidneys, peak levels only being achieved '"I-rMulti-CSF (420,000 cpm, specific radioactivity = 220,000 cpm/ng) was injected i.v. into C57BL/6 WEHI female mice (73 days old). Twelve mice were injected and pairs of mice were killed at the times indicated. Radioactivity in the blood was normalized to that for 1 g. Medical Sciences: Metcalf and Nicola 5-10 min after injection. At that time, total kidney cpm exceeded those in the much larger liver by -50%o. The decline in kidney radioactivity commenced after 10 min, and within 1 hr high levels of radioactivity were detected in the urine, the material being nonprecipitable by trichloroacetic acid and presumably representing low molecular weight degradation products.
A similar labeling pattern, but at much lower levels, was observed for the salivary gland, lung, and heart. A clearly different pattern of labeling was observed with the spleen 4, and thymus, where labeling levels rose more slowly but remained high at 30 min, by which time there had been substantial falls in other organs. As anticipated, the labeling pattern in the thyroid was unique in reaching very high levels with time, almost certainly reflecting the uptake of iodide released from the degraded 125I-Multi-CSF.
Autoradiographic Studies. Autoradiographs of organs from mice injected 20 min, 1 hr, and 2 hr previously showed a qualitatively constant labeling pattern. In the liver, labeling was concentrated over the margins of the sinusoids, indicating labeling of endothelial cells and possibly Kupffer cells (Fig. 4A) . Little label was observed over liver parenchymal cells.
In the kidney, a striking pattern was observed with intense labeling of the cells of the Bowman's capsule and proximal renal tubules (Fig. 4B ) but essentially no labeling of the glomeruli or distal tubules.
In the spleen, significant but light labeling was observed over cells in the red pulp with no labeling of the germinal centers or lymphoid follicles. A consistent feature was the occurrence of scattered, intensely labeled single cells in the red pulp and characteristically in the marginal sinus region around the lymphoid follicles (Fig. 4E) . These highly labeled cells were of small size with round nuclei.
In the gut, occasional, intensely labeled cells were observed in the base of the villi of the small intestine but no significant labeling was observed over the epithelial cells of the gut (Fig. 4C) .
In femur sections, no obvious labeling of hemopoietic cells was observed. However, in autoradiographs of cytocentrifuged preparations of marrow cells, light labeling was observed over immature granulocytes and monocytes. This was in agreement with direct cpm of washed femur marrow cells from mice injected with 3 x 106 cpm of 125I-Multi-CSF, which indicated that the total bone marrow cells bound 0.4% of the injected 125I-Multi-CSF. A characteristic feature of these cell preparations, similar to that seen with marrow populations labeled in vitro with 125I-Multi-CSF (15) , was the presence of a low percentage (<1%) of heavily labeled cells. As in the in vitro studies, these varied in morphology, most commonly being small mononuclear cells and less often having the morphology of immature granulocytes and monocytes (Fig. 4F ).
The thymic lymphoid populations, like the spleen lymphoid follicles, were unlabeled. However, a curious feature of the thymus was the presence, even after 2 hr, of prominent labeling of the endothelial cells in the radial vessels of the thymus cortex. Labeling of this intensity was not seen in vessels of corresponding size in any other organ.
In the thyroid, intense labeling was observed over the secretion products in all thyroid follicles (Fig. 4D ).
DISCUSSION
The present data indicate a rapid biphasic loss of i.v.injected Multi-CSF from the circulation and are in general agreement with earlier estimates of the serum half-life of injected Multi-CSF (1, 13, 14) , granulocyte/macrophage, granulocyte and macrophage CSFs (1, 17) , and other polypeptide regulators, such as interleukin 2 (18) . The data have emphasized a problem with radiolabeling studies in that the method can detect material that is no longer biologically active.
It is a common view that glycosylation may protect polypeptides from clearance (19) . However, the fate of nonglycosylated rMulti-CSF was generally similar to that of native Multi-CSF, and the molecular basis of CSF recognition and clearance by tissues such as the liver and kidney remains to be established.
Because it is not possible to determine what proportion of the radiolabeled material detected in tissues remains biologically active CSF, there is necessarily an element of uncertainty in discussing the exact fate of injected Multi-CSF. A high proportion of the injected Multi-CSF appears to become localized initially in the liver and shortly afterwards in the kidney. The absence of significant labeling over liver parenchymal cells suggests that these cells may not be a major site of Multi-CSF breakdown.
The striking pattern of localization of label in the kidney strongly suggests that the cells of the Bowman's capsule and proximal renal tubules are important populations degrading Multi-CSF. Labeling with this distribution has not been observed in parallel studies using the glycoprotein ovalbumin or leukemia inhibitory factor (unpublished data). That kidney cells actually degrade, rather than store, Multi-CSF is strongly suggested by the appearance of low molecular weight iodinated material in the urine within 1 hr of injection of Multi-CSF. A similar conclusion was reached in studies on the fate of macrophage-CSF (17) .
The present studies have shown that injected Multi-CSF can penetrate the marrow and spleen and successfully label hemopoietic cells in a manner comparable with that observed in in vitro labeling studies. The occurrence of heavily labeled cells in the perifollicular regions of the spleen lymphoid follicles is of considerable interest since it is in this location that foci of immature mast cells develop in mice injected with even low concentrations of rMulti-CSF (11) . Since quantitative responsiveness is likely to be correlated with receptor numbers, it seems possible that the heavily labeled cells in the perifollicular sinuses could be the cells generating the populations of immature mast cells in this location in mice injected with rMulti-CSF (11) . The heavily labeled cells seen at the base of some intestinal villi could also be similar mast cell precursors.
The organ distribution studies have therefore identified two general types of localization: (i) to liver, kidney, and thyroid, possibly associated with CSF degradation and clearance, and (ii) labeling of selected hemopoietic populationsa process likely to be based on the distribution of specific membrane receptors for Multi-CSF on these cells and leading to stimulation of proliferation or functional activation.
From a practical viewpoint of the in vivo use of the CSFs in experimental animals and in man, there is need for studies to modify the CSF molecules in a way that preserves biological activity but minimizes the rapid removal and degradation of injected CSF, probably by the liver and kidney.
